Savara (NASDAQ:SVRA) Shares Break Above Fifty Day Moving Average – Here’s Why

Savara Inc. (NASDAQ:SVRA)’s stock price passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $4.98 and traded as high as $5.07. Savara shares last traded at $5.05, with a volume of 2,400,381 shares.

Analyst Upgrades and Downgrades

SVRA has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Thursday, October 15th. Citigroup reissued a “market outperform” rating on shares of Savara in a report on Wednesday, October 7th. JPMorgan Chase & Co. assumed coverage on shares of Savara in a research report on Wednesday, October 7th. They set an “overweight” rating and a $12.00 target price for the company. Finally, Royal Bank Of Canada set a $10.00 price objective on Savara in a research report on Wednesday, October 7th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.25.

Savara Stock Up 1.4%

The company has a debt-to-equity ratio of 0.28, a quick ratio of 10.13 and a current ratio of 8.55. The firm has a 50-day moving average price of $4.96 and a two-hundred day moving average price of $5.35.

Savara (NASDAQ:SVRA) last issued its earnings results on Monday, November 9th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. On average, sell-side analysts anticipate that Savara Inc. will post -0.66 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Large investors have recently bought and sold shares of the business. Sterling Capital Management LLC lifted its position in shares of Savara by 842.8% during the third quarter. Sterling Capital Management LLC now owns 5,063 shares of the company’s stock valued at $26,000 after buying an additional 4,526 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Savara in the first quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Savara during the 3rd quarter worth about $54,000. Sequoia Financial Advisors LLC acquired a new stake in Savara during the second quarter worth about $69,000. Finally, E Fund Management Co. Ltd. purchased a new position in shares of Savara during the 2nd quarter valued at approximately $77,000. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.